Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTT | P42858 | 3/20 | 0.68 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.68 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.68 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.68 |
| ▸ | RAB9A | P51151 | 2/20 | 0.62 |
| ▸ | MAPT | P10636 | 2/20 | 0.62 |
| ▸ | HPGD | P15428 | 1/20 | 0.62 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.59 |
| ▸ | MEN1 | O00255 | 2/20 | 0.59 |
| ▸ | TTR | P02766 | 1/20 | 0.57 |
| ▸ | MTNR1B | P49286 | 1/20 | 0.52 |
| ▸ | LPAR1 | Q92633 | 5/20 | 0.52 |
| ▸ | LPAR5 | Q9H1C0 | 5/20 | 0.52 |
| ▸ | GAA | P10253 | 1/20 | 0.51 |
| ▸ | EZH2 | Q15910 | 1/20 | 0.51 |
| ▸ | PARP10 | Q53GL7 | 2/20 | 0.50 |
| ▸ | LMNA | P02545 | 2/20 | 0.49 |
| ▸ | BACE1 | P56817 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25960673 | 0.88 | RAB9A (0.56) | HTTL3MBTL1ALDH1A1MAPK1RAB9A | |
| SCHEMBL23463916 | 0.86 | ALDH1A1 (0.68) | HTTL3MBTL1ALDH1A1MAPK1RAB9A | |
| SCHEMBL1452415 | 0.86 | TTR (0.71) | HTTL3MBTL1ALDH1A1MAPK1RAB9A | |
| SCHEMBL16520985 | 0.86 | HTT (0.68) | HTTL3MBTL1ALDH1A1MAPK1RAB9A | |
| SCHEMBL13679391 | 0.84 | RAB9A (0.60) | HTTL3MBTL1ALDH1A1MAPK1RAB9A | |
| SCHEMBL9861909 | 0.84 | MAPT (0.64) | HTTL3MBTL1ALDH1A1MAPK1RAB9A | |
| SCHEMBL3627857 | 0.82 | HTT (1.00) | HTTL3MBTL1ALDH1A1MAPK1RAB9A | |
| SCHEMBL10588626 | 0.82 | MAPT (0.62) | HTTL3MBTL1ALDH1A1RAB9AMAPT | |
| SCHEMBL5608673 | 0.82 | HPGD (0.62) | L3MBTL1ALDH1A1RAB9AMAPTHPGD | |
| SCHEMBL4743129 | 0.82 | MAPT (0.62) | HTTL3MBTL1ALDH1A1RAB9AMAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-116018138-A | Substituted 1H-imidazo [1,2-b ] pyrazole-3-carboxamides as inhibitors of brunauer tyrosine kinase | 河南知微生物医药有限公司 | 2023-04-25 | — | — | CN | disclosed |
| US-20120270819-A1 | USE OF COMPOUNDS WITH SGLT-1/SGLT-2 INHIBITOR ACTIVITY FOR PRODUCING MEDICAMENTS FOR TREATMENT OF BONE DISEASE | SANOFI (FR) | 2012-10-25 | — | — | US | disclosed |
| US-20120270819-A1 | USE OF COMPOUNDS WITH SGLT-1/SGLT-2 INHIBITOR ACTIVITY FOR PRODUCING MEDICAMENTS FOR TREATMENT OF BONE DISEASE | SANOFI (FR) | 2012-10-25 | — | — | US | disclosed |
| US-20120270819-A1 | USE OF COMPOUNDS WITH SGLT-1/SGLT-2 INHIBITOR ACTIVITY FOR PRODUCING MEDICAMENTS FOR TREATMENT OF BONE DISEASE | SANOFI (FR) | 2012-10-25 | — | — | US | disclosed |
| EP-2482823-A2 | USE OF COMPOUNDS WITH SGLT-1/SGLT-2 INHIBITOR ACTIVITY FOR PRODUCING MEDICAMENTS FOR TREATMENT OF BONE DISEASES | SANOFI (FR) | 2012-08-08 | — | — | EP | disclosed |
| WO-2011039338-A2 | USE OF COMPOUNDS WITH SGLT-1/SGLT-2 INHIBITOR ACTIVITY FOR PRODUCING MEDICAMENTS FOR TREATMENT OF BONE DISEASES | SANOFI-AVENTIS (FR) | 2011-04-07 | — | — | WO | disclosed |
| WO-2011039338-A2 | USE OF COMPOUNDS WITH SGLT-1/SGLT-2 INHIBITOR ACTIVITY FOR PRODUCING MEDICAMENTS FOR TREATMENT OF BONE DISEASES | SANOFI-AVENTIS (FR) | 2011-04-07 | — | — | WO | disclosed |
| US-20080108580-A1 | NOVEL AROMATIC FLUOROGLYCOSIDE DERIVATIVES, MEDICAMENTS CONTAINING THESE COMPOUNDS, AND THE USE THEREOF | SANOFI-AVENTIS DEUTSCHLAND GMBH (DE) | 2008-05-08 | — | — | US | disclosed |
| US-20080108580-A1 | NOVEL AROMATIC FLUOROGLYCOSIDE DERIVATIVES, MEDICAMENTS CONTAINING THESE COMPOUNDS, AND THE USE THEREOF | SANOFI-AVENTIS DEUTSCHLAND GMBH (DE) | 2008-05-08 | — | — | US | disclosed |
| US-20080108580-A1 | NOVEL AROMATIC FLUOROGLYCOSIDE DERIVATIVES, MEDICAMENTS CONTAINING THESE COMPOUNDS, AND THE USE THEREOF | SANOFI-AVENTIS DEUTSCHLAND GMBH (DE) | 2008-05-08 | — | — | US | disclosed |
| US-7288528-B2 | Aromatic fluoroglycoside derivatives, medicaments containing these compounds, and the use thereof | SANOFI-AVENTIS DEUTSCHLAND GMBH (DE) | 2007-10-30 | — | — | US | disclosed |
| US-7288528-B2 | Aromatic fluoroglycoside derivatives, medicaments containing these compounds, and the use thereof | SANOFI-AVENTIS DEUTSCHLAND GMBH (DE) | 2007-10-30 | — | — | US | disclosed |
| US-7288528-B2 | Aromatic fluoroglycoside derivatives, medicaments containing these compounds, and the use thereof | SANOFI-AVENTIS DEUTSCHLAND GMBH (DE) | 2007-10-30 | — | — | US | disclosed |
| EP-1572707-B1 | NOVEL AROMATIC FLUOROGLYCOSIDE DERIVATIVES, PHARMACEUTICAL PRODUCTS CONTAINING SAID COMPOUNDS AND THE USE THEREOF | SANOFI AVENTIS DEUTSCHLAND (DE) | 2006-03-29 | — | — | EP | disclosed |
| EP-1572707-A1 | NOVEL AROMATIC FLUOROGLYCOSIDE DERIVATIVES, PHARMACEUTICAL PRODUCTS CONTAINING SAID COMPOUNDS AND THE USE THEREOF | Aventis Pharma Deutschland GmbH (DE) | 2005-09-14 | — | — | EP | disclosed |
| US-20050014704-A1 | Novel aromatic fluoroglycoside derivatives, medicaments containing these compounds, and the use thereof | AVENTIS PHARMA DEUTSCHLAND GMBH (DE) | 2005-01-20 | — | — | US | disclosed |
| WO-2004052902-A1 | NOVEL AROMATIC FLUOROGLYCOSIDE DERIVATIVES, PHARMACEUTICAL PRODUCTS CONTAINING SAID COMPOUNDS AND THE USE THEREOF | AVENTIS PHARMA DEUTSCHLAND GMBH (DE) | 2004-06-24 | — | — | WO | disclosed |
| CN-87108295-A | New alkane sulfonyl aniline derivative and its medicinal compositions and preparation method | — | 1988-07-13 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080108580-A1 | NOVEL AROMATIC FLUOROGLYCOSIDE DERIVATIVES, MEDICAMENTS CONTAINING THESE COMPOUNDS, AND THE USE THEREOF | SLC5A2, SLC5A1, UGGT1 | HTT 3180/4885L3MBTL1 4769/4885ALDH1A1 745/4885 |
| US-20050014704-A1 | Novel aromatic fluoroglycoside derivatives, medicaments containing these compounds, and the use thereof | SLC5A2, SLC5A1, UGGT1 | HTT 3180/4885L3MBTL1 4769/4885ALDH1A1 745/4885 |
| US-20120270819-A1 | USE OF COMPOUNDS WITH SGLT-1/SGLT-2 INHIBITOR ACTIVITY FOR PRODUCING MEDICAMENTS FOR TREATMENT OF BONE DISEASE | SLC5A1, SLC5A2, SOST | HTT 2149/4885L3MBTL1 4033/4885ALDH1A1 855/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.